DE69940265D1 - Alzheimersche krankheit sekretase - Google Patents

Alzheimersche krankheit sekretase

Info

Publication number: DE69940265D1
Authority: DE; Germany
Prior art keywords: alzheimersche; sekretase; disease; cleaving; assays
Prior art date: 1998-09-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69940265T

Other languages

English (en)

Inventor

Mark E Gurney

Michael Jerome Bienkowski

Robert Leroy Heinrikson

Luis A Parodi

Riqiang Yan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co LLC

Original Assignee

Pharmacia and Upjohn Co LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-24

Filing date

1999-09-23

Publication date

2009-02-26

1999-09-23 Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC

2009-02-26 Application granted granted Critical

2009-02-26 Publication of DE69940265D1 publication Critical patent/DE69940265D1/de

2019-09-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69940265T 1998-09-24 1999-09-23 Alzheimersche krankheit sekretase Expired - Lifetime DE69940265D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10159498P	1998-09-24	1998-09-24
PCT/US1999/020881 WO2000017369A2 (en)	1998-09-24	1999-09-23	Alzheimer's disease secretase

Publications (1)

Publication Number	Publication Date
DE69940265D1 true DE69940265D1 (de)	2009-02-26

Family

ID=22285461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69940265T Expired - Lifetime DE69940265D1 (de)	1998-09-24	1999-09-23	Alzheimersche krankheit sekretase

Country Status (28)

Country	Link
US (2)	US6835565B1 (de)
EP (1)	EP1115874B1 (de)
JP (3)	JP2002526081A (de)
KR (8)	KR20060111905A (de)
CN (4)	CN1300320C (de)
AT (1)	ATE420185T1 (de)
AU (2)	AU772812C (de)
BR (1)	BR9913920A (de)
CA (1)	CA2343004A1 (de)
CY (1)	CY1111006T1 (de)
CZ (1)	CZ2001966A3 (de)
DE (1)	DE69940265D1 (de)
DK (1)	DK1115874T3 (de)
EA (1)	EA009216B1 (de)
ES (1)	ES2318902T3 (de)
HK (2)	HK1042730B (de)
HU (1)	HUP0103838A3 (de)
IL (2)	IL142207A (de)
IS (1)	IS5905A (de)
NO (1)	NO20011505L (de)
NZ (2)	NZ510708A (de)
PL (1)	PL205294B1 (de)
PT (1)	PT1115874E (de)
SG (1)	SG113454A1 (de)
SK (1)	SK3902001A3 (de)
TR (3)	TR200200662T2 (de)
WO (1)	WO2000017369A2 (de)
ZA (1)	ZA200102387B (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9701684D0 (en)	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
AU1726199A (en)	1997-12-31	1999-07-19	Chiron Corporation	Metastatic cancer regulated gene
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
KR20060111905A (ko)	1998-09-24	2006-10-30	파마시아 앤드 업존 캄파니 엘엘씨	알츠하이머병 세크레타제
US6699671B1 (en) *	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7115410B1 (en)	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
AU4000900A (en) *	1999-02-10	2000-08-29	Elan Pharmaceuticals, Inc.	Beta-secretase enzyme compositions and methods
AU3770800A (en)	1999-03-26	2000-10-16	Amgen, Inc.	Beta secretase genes and polypeptides
AU5771500A (en)	1999-06-28	2001-01-31	Oklahoma Medical Research Foundation	Catalytically active recombinant memapsin and methods of use thereof
EP1496124A1 (de) *	1999-06-28	2005-01-12	Oklahoma Medical Research Foundation	Katalytisch wirksame rekombinierte Memapsin und Verfahren zur Verwendung davon
AU782312B2 (en) *	1999-09-23	2005-07-21	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en)	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
JP2003528071A (ja)	2000-03-23	2003-09-24	エランファーマスーティカルズインコーポレイテッド	アルツハイマー病治療用組成物および方法
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6686449B2 (en)	2000-06-30	2004-02-03	Pharmacia & Upjohn Company	Mutant presenilin 1 polypeptides
AU2001273113A1 (en)	2000-06-30	2002-01-14	Elan Pharmaceuticals, Inc	Compounds to treat alzheimer's disease
US7205120B2 (en)	2000-07-19	2007-04-17	Pharmacia & Upjohn Company	Substrates and assays for β-secretase activity
US20030190635A1 (en) *	2002-02-20	2003-10-09	Mcswiggen James A.	RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US7806980B2 (en)	2000-12-23	2010-10-05	Elan Pharmaceuticals, Inc.	Method for crystallizing human beta secretase in complex with an inhibitor
EP1434988A4 (de)	2001-02-23	2005-12-14	Elan Pharm Inc	Transgene bace-1-knockouts
US7524668B1 (en)	2001-05-10	2009-04-28	Elan Pharmaceuticals, Inc.	Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005508141A (ja)	2001-05-25	2005-03-31	セローノジェネティクスインスティテュートソシエテアニニム	ヒトｃＤＮＡおよびタンパク質、ならびにそれらの使用
DE60226729D1 (de)	2001-06-01	2008-07-03	Elan Pharm Inc	Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
CA2449948A1 (en) *	2001-06-08	2002-12-19	Elan Pharmaceuticals, Inc.	Methods of treating alzheimer's disease
WO2002100818A2 (en)	2001-06-13	2002-12-19	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
MXPA04000140A (es)	2001-06-27	2004-06-03	Elan Pharm Inc	Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
JP2005505517A (ja)	2001-07-10	2005-02-24	イーランファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療するためのアミンジオール
CA2453447A1 (en)	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
BR0211118A (pt)	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7186539B1 (en)	2001-08-31	2007-03-06	Pharmacia & Upjohn Company	Method for refolding enzymes
CA2462851A1 (en)	2001-10-04	2003-04-10	Elan Pharmaceuticals, Inc.	Hydroxypropylamines
JP4547152B2 (ja)	2001-10-23	2010-09-22	オクラホマメディカルリサーチファウンデーション	β−セクレターゼ阻害剤および使用方法
AU2002359376B2 (en)	2001-11-08	2008-01-10	Elan Pharmaceuticals, Inc.	N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214359A (pt) *	2001-11-21	2004-10-13	Elan Pharm Inc	Método para tratar ou prevenir o mal de alzheimer e uma doença e para tratar um paciente que tem, ou para prevenir que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor amilóide e a produção de peptìdeo e de placa beta-amilóide e para produzir um complexo de beta-secretase, uso de um composto e, composição
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2003072733A2 (en)	2002-02-21	2003-09-04	Pharmacia & Upjohn Company	Modified bace
US7262208B2 (en)	2002-04-30	2007-08-28	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of Alzheimer's disease
US7442537B1 (en)	2002-05-10	2008-10-28	Elan Pharmaceuticals, Inc.	Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US7956176B2 (en)	2002-09-05	2011-06-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
UY27967A1 (es)	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
BR0316629A (pt)	2002-11-27	2005-10-11	Elan Pharm Inc	Uréias e carbamatos substituìdos
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
TW200512195A (en)	2003-04-21	2005-04-01	Elan Pharm Inc	Benzamide 2-hydroxy-3-diaminoalkanes
EP1473362A1 (de)	2003-05-02	2004-11-03	Elan Pharmaceuticals, Inc.	BACE Glykosylierungsvarianten
JP2007528400A (ja)	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2006010095A2 (en)	2004-07-09	2006-01-26	Elan Pharmaceuticals Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
JP2008505929A (ja)	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2006081171A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
EP1863771B1 (de) *	2005-03-14	2012-11-07	High Point Pharmaceuticals, LLC	Benzazolderivate, zusammensetzungen und anwendungsverfahren als b-sekretase-inhibitoren
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
WO2007047305A1 (en)	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838676B2 (en)	2005-11-21	2010-11-23	Amgen Inc.	Beta-secretase modulators and methods of use
US7872009B2 (en)	2005-11-21	2011-01-18	Amgen Inc.	Beta-Secretase modulators and methods of use
US7745484B2 (en)	2005-11-21	2010-06-29	Amgen Inc.	Beta-secretase modulators and methods of use
US20070292895A1 (en) *	2006-05-19	2007-12-20	Xiao-Ping Shi	Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
EP1865326B1 (de) *	2006-06-08	2011-09-07	FU Berlin	Assay zur Diagnose von Alzheimer basierend auf der Bestimmung des Verhältnisses von Sekretase-Aß-Spaltprodukten
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
CA2687608C (en)	2007-05-25	2013-07-02	Amgen Inc.	Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2008147547A1 (en)	2007-05-25	2008-12-04	Amgen Inc.	Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
JP5450407B2 (ja)	2007-07-06	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
US7803809B2 (en)	2008-11-12	2010-09-28	Amgen Inc.	Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
ES2459195T3 (es) *	2008-09-11	2014-05-08	Amgen Inc.	Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
TW201020244A (en)	2008-11-14	2010-06-01	Astrazeneca Ab	New compounds
EP2281824A1 (de)	2009-08-07	2011-02-09	Noscira, S.A.	Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
EP2504315A1 (de)	2009-11-23	2012-10-03	Amgen Inc.	Aminoheteroarylverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
EP2504330A1 (de)	2009-11-23	2012-10-03	Amgen Inc.	Aminoheteroarylverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
US8735384B2 (en)	2010-01-19	2014-05-27	Amgen Inc.	Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP2013522305A (ja)	2010-03-15	2013-06-13	アムジエン・インコーポレーテツド	β−セクレターゼ調節剤としてのスピロ−四環式環化合物
EP2547686B1 (de)	2010-03-15	2014-01-22	Amgen Inc.	Amino-dihydrooxazin- und amino-dihydrothiazin-spiro-verbindungen als beta-secretase modulatoren und deren medizinische verwendung
US8921363B2 (en)	2010-08-05	2014-12-30	Amgen Inc.	Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
AU2011291506B2 (en)	2010-08-19	2016-07-28	Buck Institute For Age Research	Methods of treating mild cognitive impairment (mci) and related disorders
EP3766975A1 (de)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2643299B1 (de)	2010-11-22	2016-06-22	Noscira, S.A.	Bipyridinsulfonamidderivate zur behandlung von neurodegenerativen erkrankungen oder zuständen
US8957083B2 (en)	2010-11-23	2015-02-17	Amgen Inc.	Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (de)	2011-02-07	2013-12-18	Amgen Inc.	5-amino-oxazepin- und 5-amino-thiazepanverbindungen als beta-sekretase-antagonisten und verwendungsverfahren
WO2012112462A1 (en)	2011-02-15	2012-08-23	Amgen Inc.	Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2013044092A1 (en)	2011-09-21	2013-03-28	Amgen Inc.	Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN106902108B (zh)	2012-03-19	2020-07-21	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
US9556135B2 (en)	2012-10-12	2017-01-31	Amgen, Inc.	Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
US9725469B2 (en)	2012-11-15	2017-08-08	Amgen, Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9309263B2 (en)	2013-01-29	2016-04-12	Amgen Inc.	Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
US10202355B2 (en)	2013-02-12	2019-02-12	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
JP6389830B2 (ja)	2013-03-01	2018-09-12	アムジエン・インコーポレーテツド	ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
CN105164121A (zh)	2013-03-08	2015-12-16	美国安进公司	作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法
US9096615B2 (en)	2013-07-30	2015-08-04	Amgen Inc.	Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
KR101791296B1 (ko)	2014-04-17	2017-10-27	제주대학교 산학협력단	알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주
WO2016022724A1 (en)	2014-08-08	2016-02-11	Amgen Inc.	Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP3290525B1 (de)	2015-04-30	2022-02-23	Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd.	Verfahren zum screening von wirkstoffen und therapeutischen targets zur behandlung von morbus alzheimer
WO2017024180A1 (en)	2015-08-06	2017-02-09	Amgen Inc.	Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP3341362B1 (de)	2015-08-27	2023-07-05	Nantneuro, LLC	Zusammensetzungen zur app-selektiven bace-hemmung und verwendungen dafür
IL262957B2 (en)	2016-05-12	2024-04-01	Buck Inst Res Aging	6-Fluorotropistrone and a pharmaceutical formulation comprising it for the relief of amyloid-related diseases
CA3047288A1 (en)	2016-12-15	2018-06-21	Amgen Inc.	Thiazine derivatives as beta-secretase inhibitors and methods of use
MX386618B (es)	2016-12-15	2025-03-19	Amgen Inc	Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
AU2017376446B2 (en)	2016-12-15	2021-10-14	Amgen Inc.	1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
EP3555080B1 (de)	2016-12-15	2023-09-20	Amgen Inc.	Oxazinderivate als beta-sekretase-hemmer und verfahren zur verwendung
US11548903B2 (en)	2016-12-15	2023-01-10	Amgen Inc.	Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
CN107576785A (zh) *	2017-08-25	2018-01-12	广州市雷德生物科技有限公司	一种样本处理液及其应用
GB201803010D0 (en) *	2018-02-26	2018-04-11	Royal Holloway & Bedford New College	Neurodegenerative disorders
CN111518793A (zh) *	2020-05-20	2020-08-11	谭骏	年轻人血源APPα-分泌酶在阿尔茨海默病中的应用
CN114480494B (zh) *	2022-02-10	2024-07-05	中国科学技术大学	蛋白探针以及其在检测bace1活性中的应用
WO2024087429A1 (zh) *	2023-02-28	2024-05-02	湖南乾康科技有限公司	用于检测蛋白生物标志物组的抗体在制备诊断ad、mci和其它类型老年痴呆的试剂盒中的用途
CN118831181B (zh) *	2024-09-20	2025-02-11	江苏集萃药康生物科技股份有限公司	一种三突变阿尔兹海默症小鼠模型的构建方法及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5200339A (en)	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
US5292652A (en)	1990-10-05	1994-03-08	Athena Neurosciences, Inc.	Amyloidin protease and uses thereof
EP0568575B2 (de)	1991-01-21	2010-11-03	Elan Pharmaceuticals, Inc.	Prüfung und modell für alzheimers-krankheit
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
TW327194B (en) *	1992-05-01	1998-02-21	American Cyanamid Co	Novel amyloid precursor proteins and methods of using same
IL105793A0 (en)	1992-05-28	1993-09-22	Lilly Co Eli	Protease and related dna compounds
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5605811A (en) *	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
CA2151927A1 (en) *	1992-12-16	1994-06-23	Paul Perry Tamburini	Cathepsin d is an amyloidogenic protease in alzheimer's disease
EP0608546A3 (en) *	1992-12-22	1995-09-27	Takeda Chemical Industries Ltd	Glia activating factor (gaf), antibodies against it and their uses.
WO1994017197A1 (en)	1993-01-25	1994-08-04	Takeda Chemical Industries, Ltd.	ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF
JPH09507746A (ja)	1993-10-27	1997-08-12	アテナニューロサイエンシズ，インコーポレイティド	Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
CA2198451A1 (en)	1994-09-01	1996-03-07	Gurparkash Singh	Transgenic animal expressing a familial form of human amyloid precursor protein
CA2217492A1 (en)	1995-04-04	1996-10-10	Edward Marion Johnstone	Amyloid precursor protein protease
US5744346A (en)	1995-06-07	1998-04-28	Athena Neurosciences, Inc.	β-secretase
US5942400A (en)	1995-06-07	1999-08-24	Elan Pharmaceuticals, Inc.	Assays for detecting β-secretase
US6221645B1 (en)	1995-06-07	2001-04-24	Elan Pharmaceuticals, Inc.	β-secretase antibody
DE19641180A1 (de)	1996-09-24	1998-03-26	Schering Ag	Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998021589A1 (en)	1996-11-15	1998-05-22	The Trustees Of The University Of Pennsylvania	Screening for modulators of amyloid processing
AU1684097A (en) *	1996-12-11	1998-07-03	Athena Neurosciences, Inc.	Beta-secretase isolated from human 293 cells
GB9626022D0 (en)	1996-12-14	1997-01-29	Smithkline Beecham Plc	Novel compounds
EP0848062A3 (de) *	1996-12-14	2000-07-05	Smithkline Beecham Corporation	Aspartylprotease ASP1
GB9701684D0 (en)	1997-01-28	1997-03-19	Smithkline Beecham Plc	Novel compounds
GB9721094D0 (en) *	1997-10-03	1997-12-03	Unilever Plc	Autophobic hairspray compositions
DE69841110D1 (de)	1997-12-17	2009-10-08	Serono Genetics Inst Sa	Verlängerte cdns, die für sekretierte proteine kodieren
AU1726199A (en) *	1997-12-31	1999-07-19	Chiron Corporation	Metastatic cancer regulated gene
PT1490386E (pt) *	1998-03-10	2008-11-24	Genentech Inc	Novos polipéptidos e ácidos nucleicos que os codificam
EP1084240A1 (de)	1998-06-05	2001-03-21	Aventis Pharma S.A.	Polypeptiden mit beta-sekretase aktivität
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20060111905A (ko)	1998-09-24	2006-10-30	파마시아 앤드 업존 캄파니 엘엘씨	알츠하이머병 세크레타제
US6245884B1 (en)	1998-10-16	2001-06-12	Vivian Y. H. Hook	Secretases related to alzheimer's dementia
US6313268B1 (en)	1998-10-16	2001-11-06	Vivian Y. H. Hook	Secretases related to Alzheimer's dementia
AU4000900A (en)	1999-02-10	2000-08-29	Elan Pharmaceuticals, Inc.	Beta-secretase enzyme compositions and methods
DE19910108C2 (de)	1999-03-08	2001-02-22	Falk Fahrenholz	Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie
AU3770800A (en)	1999-03-26	2000-10-16	Amgen, Inc.	Beta secretase genes and polypeptides
AU4640600A (en)	1999-05-11	2000-11-21	Eli Lilly And Company	Amyloid precursor protein protease and related nucleic acid compounds
US7087399B1 (en)	1999-05-13	2006-08-08	Scios, Inc.	β-secretase and modulation of β-secretase activity
AU5771500A (en)	1999-06-28	2001-01-31	Oklahoma Medical Research Foundation	Catalytically active recombinant memapsin and methods of use thereof
GB9924957D0 (en)	1999-10-21	1999-12-22	Smithkline Beecham Plc	Novel treatment
GB9925136D0 (en)	1999-10-22	1999-12-22	Smithkline Beecham Plc	Novel treatment
US6361975B1 (en)	1999-11-16	2002-03-26	Smithkline Beecham Corporation	Mouse aspartic secretase-2(mASP-2)
US6291223B1 (en)	1999-11-23	2001-09-18	Smithkline Beecham Corporation	Mouse aspartic secretase-1 (mASP1)

1999
- 1999-09-23 KR KR1020067020982A patent/KR20060111905A/ko not_active Withdrawn
- 1999-09-23 NZ NZ510708A patent/NZ510708A/en not_active IP Right Cessation
- 1999-09-23 CZ CZ2001966A patent/CZ2001966A3/cs unknown
- 1999-09-23 KR KR1020047015171A patent/KR100768381B1/ko not_active Expired - Fee Related
- 1999-09-23 KR KR1020017003744A patent/KR100839284B1/ko not_active Expired - Fee Related
- 1999-09-23 JP JP2000574268A patent/JP2002526081A/ja active Pending
- 1999-09-23 KR KR1020067025867A patent/KR20070004143A/ko not_active Abandoned
- 1999-09-23 TR TR2002/00662T patent/TR200200662T2/xx unknown
- 1999-09-23 CN CNB2003101196656A patent/CN1300320C/zh not_active Expired - Fee Related
- 1999-09-23 CA CA002343004A patent/CA2343004A1/en not_active Abandoned
- 1999-09-23 US US09/806,194 patent/US6835565B1/en not_active Expired - Fee Related
- 1999-09-23 PT PT99948189T patent/PT1115874E/pt unknown
- 1999-09-23 KR KR1020047015170A patent/KR100866676B1/ko not_active Expired - Fee Related
- 1999-09-23 CN CNA2003101196637A patent/CN1502692A/zh active Pending
- 1999-09-23 KR KR1020067023390A patent/KR20060126626A/ko not_active Withdrawn
- 1999-09-23 CN CNB99811202XA patent/CN1198936C/zh not_active Expired - Fee Related
- 1999-09-23 DK DK99948189T patent/DK1115874T3/da active
- 1999-09-23 TR TR2006/01231T patent/TR200601231T2/xx unknown
- 1999-09-23 WO PCT/US1999/020881 patent/WO2000017369A2/en active Application Filing
- 1999-09-23 BR BR9913920-0A patent/BR9913920A/pt not_active Application Discontinuation
- 1999-09-23 AT AT99948189T patent/ATE420185T1/de active
- 1999-09-23 ES ES99948189T patent/ES2318902T3/es not_active Expired - Lifetime
- 1999-09-23 EP EP99948189A patent/EP1115874B1/de not_active Expired - Lifetime
- 1999-09-23 SK SK390-2001A patent/SK3902001A3/sk unknown
- 1999-09-23 SG SG200301440A patent/SG113454A1/en unknown
- 1999-09-23 EA EA200100387A patent/EA009216B1/ru not_active IP Right Cessation
- 1999-09-23 DE DE69940265T patent/DE69940265D1/de not_active Expired - Lifetime
- 1999-09-23 KR KR1020077000411A patent/KR20070013361A/ko not_active Withdrawn
- 1999-09-23 HU HU0103838A patent/HUP0103838A3/hu unknown
- 1999-09-23 KR KR1020047015172A patent/KR100691601B1/ko not_active Expired - Fee Related
- 1999-09-23 TR TR2001/01484T patent/TR200101484T2/xx unknown
- 1999-09-23 CN CNA2003101196641A patent/CN1502696A/zh active Pending
- 1999-09-23 NZ NZ527053A patent/NZ527053A/xx not_active IP Right Cessation
- 1999-09-23 AU AU61418/99A patent/AU772812C/en not_active Ceased
- 1999-09-23 PL PL348629A patent/PL205294B1/pl not_active IP Right Cessation
2001
- 2001-03-22 ZA ZA200102387A patent/ZA200102387B/en unknown
- 2001-03-22 IL IL142207A patent/IL142207A/en not_active IP Right Cessation
- 2001-03-22 IS IS5905A patent/IS5905A/is unknown
- 2001-03-23 NO NO20011505A patent/NO20011505L/no not_active Application Discontinuation
2002
- 2002-05-31 HK HK02104092.7A patent/HK1042730B/zh not_active IP Right Cessation
2004
- 2004-07-14 HK HK04105123A patent/HK1062187A1/xx not_active IP Right Cessation
- 2004-08-04 AU AU2004203588A patent/AU2004203588B2/en not_active Ceased
- 2004-09-14 US US10/940,867 patent/US7812123B2/en not_active Expired - Lifetime
2007
- 2007-03-20 IL IL182070A patent/IL182070A0/en not_active IP Right Cessation
- 2007-12-12 JP JP2007320832A patent/JP2008113665A/ja not_active Withdrawn
2009
- 2009-02-18 CY CY20091100178T patent/CY1111006T1/el unknown
- 2009-06-10 JP JP2009139454A patent/JP2009201517A/ja active Pending

Also Published As

Publication number	Publication date
KR20070004143A (ko)	2007-01-05
CA2343004A1 (en)	2000-03-30
NZ527053A (en)	2005-04-29
NZ510708A (en)	2003-12-19
HK1042730B (zh)	2005-11-18
HUP0103838A2 (hu)	2002-03-28
KR20040093193A (ko)	2004-11-04
KR100866676B1 (ko)	2008-11-11
KR100839284B1 (ko)	2008-06-17
CN1300320C (zh)	2007-02-14
ATE420185T1 (de)	2009-01-15
AU2004203588B2 (en)	2007-11-22
KR100768381B1 (ko)	2007-10-18
PL205294B1 (pl)	2010-03-31
WO2000017369B1 (en)	2000-12-28
KR20040097216A (ko)	2004-11-17
TR200601231T2 (tr)	2006-09-21
BR9913920A (pt)	2001-11-06
CZ2001966A3 (cs)	2001-10-17
KR100691601B1 (ko)	2007-03-09
WO2000017369A2 (en)	2000-03-30
KR20060111905A (ko)	2006-10-30
TR200101484T2 (tr)	2002-06-21
HUP0103838A3 (en)	2006-05-29
IS5905A (is)	2001-03-22
SK3902001A3 (en)	2001-12-03
AU2004203588A1 (en)	2004-09-02
AU772812C (en)	2004-12-09
JP2008113665A (ja)	2008-05-22
US6835565B1 (en)	2004-12-28
US20050026256A1 (en)	2005-02-03
JP2009201517A (ja)	2009-09-10
IL142207A (en)	2010-11-30
EA009216B1 (ru)	2007-12-28
PT1115874E (pt)	2009-04-09
IL182070A0 (en)	2007-07-24
EP1115874B1 (de)	2009-01-07
KR20010085837A (ko)	2001-09-07
AU772812B2 (en)	2004-05-06
ZA200102387B (en)	2002-09-23
CN1502692A (zh)	2004-06-09
NO20011505L (no)	2001-05-23
NO20011505D0 (no)	2001-03-23
TR200200662T2 (tr)	2002-06-21
CN1502697A (zh)	2004-06-09
DK1115874T3 (da)	2009-04-20
KR20060126626A (ko)	2006-12-07
KR20040099362A (ko)	2004-11-26
HK1062187A1 (en)	2004-10-21
KR20070013361A (ko)	2007-01-30
WO2000017369A3 (en)	2000-11-23
ES2318902T3 (es)	2009-05-01
EP1115874A2 (de)	2001-07-18
SG113454A1 (en)	2005-08-29
CN1339066A (zh)	2002-03-06
EA200100387A1 (ru)	2001-10-22
US7812123B2 (en)	2010-10-12
CN1198936C (zh)	2005-04-27
CY1111006T1 (el)	2015-06-11
JP2002526081A (ja)	2002-08-20
PL348629A1 (en)	2002-06-03
CN1502696A (zh)	2004-06-09
AU6141899A (en)	2000-04-10
HK1042730A1 (en)	2002-08-23

Publication	Publication Date	Title
DE69940265D1 (de)	2009-02-26	Alzheimersche krankheit sekretase
WO2001049097A3 (en)	2003-11-20	Alzheimer's disease secretase, app substrates therefor, and uses therefor
TW200745552A (en)	2007-12-16	HU-ASP 1 protease substrate and uses thereof
ATE352638T1 (de)	2007-02-15	REVERSE ßTWO-HYBRIDß-SYSTEME
DE60144145D1 (de)	2011-04-14	Subtilisin-variante
WO2002006457A3 (en)	2002-10-17	Novel lipase genes
CA2263713A1 (en)	1999-01-07	Lyophilization of cultured human cells to preserve rna and dna
TR199802503A3 (tr)	1999-06-21	Endojen gen aktivasyonu için hücrelerin optimizasyonu.
WO1999025878A3 (en)	1999-10-28	Methods for modulating and identifying cellular senescence
PT1025245E (pt)	2006-08-31	Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
DE69928395D1 (de)	2005-12-22	Cyclin-e2 proteine und dafür kodierende gene
AU2900400A (en)	2000-09-28	Intact cell assay for protein tyrosine phosphatases
WO2001064912A3 (en)	2002-05-10	Triazine degrading enzymes
NO20003880L (no)	2000-07-28	Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser
WO1999047673A3 (en)	1999-11-18	Isolated mammalian membrane protein genes and related reagents
WO2001066709A3 (en)	2002-05-16	Sphingomyelinase enzymes and uses relating thereto
WO2002074921A3 (en)	2004-02-26	Methods for isolating proteins expressed by dendritic cells
CY1110496T1 (el)	2015-04-29	Σεκρεταση νοσου alzheimer, υποστρωματα app αυτης, και χρησεις αυτης
WO2002050243A3 (en)	2003-10-30	The use of ecm degrading enzymes for the improvement of cell transplantation
GB2289125A (en)	1995-11-08	Methods of assaying data-repairing enzymes and their alkylated derivatives
ECSP003672A (es)	2001-04-23	Secretasa en la enfermedad de alzheimer, substratos de la app y sus usos
DK1141337T3 (da)	2011-03-14	Gram-positive bakterier, som mangler HtrA-proteaseaktivitet, samt deres anvendelser
TH51992A (th)	2002-07-16	ซีครีเทสของโรคแอลซ์ไฮม์เมอร์ app สับสเตรทของมัน และการใช้งานของมัน
PT1121146E (pt)	2004-10-29	Processo para influenciar celulas t hiperactivas por meio de enzimas proteoliticas
WO2004022702A3 (en)	2004-09-02	Methods and reagents for identifying inhibitors of viral protease activity.

Legal Events

Date	Code	Title	Description
2010-01-28	8364	No opposition during term of opposition